A board to discuss future MS therapies in early stage (Phase I or II) trials.


Postby WarmOutToday » Wed Dec 18, 2013 2:23 pm

Ibudilast (development codes: AV-411 or MN-166) is an antiinflammatory drug used mainly in Japan, which acts as a phosphodiesterase inhibitor, inhibiting the PDE-4 subtype to the greatest extent, but also showing significant inhibition of other PDE subtypes.
Ibudilast has bronchodilator, vasodilator [4] and neuroprotective effects, and is mainly used in the treatment of asthma and stroke. It inhibits platelet aggregation, and may also be useful in the treatment of multiple sclerosis.
Ibudilast crosses the blood–brain barrier and suppresses glial cell activation. This activity has been shown to make ibudilast useful in the treatment of neuropathic pain and it not only enhances analgesia produced by opioid drugs, but also reduces the development of tolerance.
It may have some use reducing methamphetamine addiction.


i don't live to far from the Medicinova, the company trying to push it through in the US, and had a chance to talk to them about it. cool stuff.

this is from them...
Phase 2 Clinical proof-of-concept for safety, tolerability, and
neuroregultaory (MS) efficacy. Neuropathic Pain POC-ready.

Preclinical Data: MN166 reduces apoptosis and
demyelination in Twitcher mice

Family Member
Posts: 34
Joined: Mon May 06, 2013 3:56 pm


Return to Drug Pipeline


  • Related topics
    Last post

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service